DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

MEMORANDUM

To: Review Committee Chair, STN 125612

From: Grainne Tobin, Biologist, LACBRP, DBSQC, OCBQ

Through: Lokesh Bhattacharyya, PhD, Chief, LACBRP, DBSQC, OCBQ

William McCormick, PhD, Director, DBSQC, OCBQ

Sponsor/Product: Octapharma Pharmazeutika Produktionsges.m.b.H.. /Fibrinogen (Human), Product name: Fibryna

Subject: In-support testing to measure the fibrinogen content using the Fibrinogen Content by (b) (4) method for Licensing Action of Fibryna, STN 125612

Summary

The fibrinogen content of five lots of Fibryna (Fibrinogen (Human)) drug product (STN 125612) were measured against the (b) (4) for Fibrinogen Plasma, (b) (4), using the Fibrinogen content by (b) (4) method. All five lots were within the proposed specifications for the fibrinogen content.

Background

A request was made by the review committee Chair to measure the fibrinogen content of five lots of Fibryna drug product using the Fibrinogen Content by (b) (4) method.

Method

The fibrinogen content of five lots of Fibryna drug product was measured at LACBRP / DBSQC/ CBER using the fibrinogen content by (b) (4) assay as described by the manufacturer, with the following modifications:

- (b) (4) was used instead of (b) (4), as (b) (4) is not commercially available in the US
- The (b) (4) for Fibrinogen Concentrate, (b) (4), was used as the control sample instead of the control reagent (b) (4) provided by the manufacturer

The clotting times were measured using a (b) (4). (b) (4) different concentrations of control and sample were measured

within the testing range ((b) (4)) and the results reported as the mean of the (b) (4) determinations. The assay was carried out once.

Results

The standard curve was established by linear regression analysis of the (b) (4) of the standard. The results of the assay validity criteria are shown in Table 1.

Table 1: Assay Validity criteria

Assay Validity Criteria	**CBER Results for Assay Validity Criteria**
R^2 standard (b) (4)	1.00
%RSD of (b) (4) dilutions of Positive Control (b) (4)	1.92 %

Table 1 shows that the R^2 value of the standard curve and the %RSD of the (b) (4) dilutions of the control met the respective acceptance criteria proposed in the BLA.

The results for the fibrinogen content are presented in Table 2.

Table 2: Fibrinogen measurements at CBER using the Fibrinogen Content by (b) (4) method

Lot Number	Proposed Spec. (mg/mL)	Manufacturer's Results (mg/mL)[1]	CBER Results (mg/mL)	CBER/Manufacturer Results Ratio (%)
A423A347/U	(b) (4)	22	22	100
A440A347/U		21	21	100
A425A347/U		22	22	100
A433A347/U		24	20	83.3
A441A347/U		21	20	95.2

[1]Manufacturer's Fibrinogen values were taken from the Lot Release Protocols included in 125612/0.13 Section 3.2.P.5.1 Specifications

Table 2 shows that the results from all five lots were within the proposed specification. The ratio of CBER's results to that of the manufacturer is 83.3% – 100%. In addition, the %RSD between (b) (4) measurements ranged from (b) (4), which met the acceptance criteria of (b) (4).

Conclusions

The results presented in Table 2 show that all five lots of Fibryna drug product tested in the Fibrinogen by (b) (4) were within specifications.